News | January 25, 2025
Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
Q3 FY25 revenue up 24% to Rs 3,230 crore
Q3 FY25 revenue up 24% to Rs 3,230 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
In 2023, Endox had revenues of approximately SEK 65 million
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Divestment is part of BASF’s strategic portfolio optimization
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Subscribe To Our Newsletter & Stay Updated
